CanBiotech 2004 Venture Capital Directory Profiles
Atlas Venture, Inc.
Address: About Us
890 Winter Street Suite 320 Atlas Venture is the leading international early-stage venture
Waltham, MA 02451 capital firm, investing in communications, information
UNITED STATES technology and life sciences companies. Atlas Venture has
Map It investing offices in Boston, London, Menlo Park, Munich, Paris
and Seattle, and its investments are evenly divided between
the United States and Europe.
T: (781) 622-1700 Founded in 1980, Atlas Venture has organized six international
F: (781) 622-1701 funds, and currently manages more than $2.4 billion in
E: email@example.com committed capital.
Company Contacts: The Life Sciences investment team offers portfolio companies
Peter Barrett expertise in biotechnology licensing and marketing, business
Boston management, and medical practice.
Jean-François Formela Preferred Stage
Boston Many of Atlas Venture’s Life Sciences portfolio companies are
developing new platform technologies to leverage the data
Paul Pospisil generated from the human genome project and enhance the
Boston drug discovery process. Others are developing new medical
devices, or using the Internet to streamline drug development
and healthcare delivery.
www.atlasventure.com/ Geographic Focus
With more than twenty years in international venture
Other Locations investing, the Atlas Venture team has developed a vast
1201 Third Avenue international network of business contacts to help portfolio
Suite 5450 companies make connections quickly. With offices and local
Seattle, WA 98101, USA contacts in major American and European markets, can
provide practical assistance to companies expanding
t: +1 206 694 8600 operations to other countries.
f: +1 206 254 9130
e: firstname.lastname@example.org Capital
More than $2.4 billion in committed capital
Acambis Plc, Achillion Pharmaceuticals, Inc, Actelion
Pharmaceuticals Ltd, Akceli, Inc, Allelix Biopharmaceuticals
Inc, Alnylam Pharmaceuticals, Inc., Anadys Pharmaceuticals,
Archemix Corp, ArQule, Inc, Artemis Pharmaceuticals GmbH,
Aureon Biosciences, Axovan Ltd., Boston Medical Technologies,
Inc CellZome GmbH, Ciphergen Biosystems, Inc, CropDesign
NV, Crucell NV, deCODE genetics, Inc, DeveloGen AG, EntoMed
SA, Exelixis, Inc, Hexagen Plc, Immuno-Designed Molecules
SA, IsoTis NV, Kriton Medical, MediGene AG, Microcide, Inc,
Micromet AG, Modex Therapeutiques SA, MorphoSys AG,
Neurochem, Inc, Neurotech SA, Newron Pharmaceuticals,
Novuspharma S.p.A., NxStage Medical, Oxford GlycoSciences
Plc, Percardia Inc, Prolifix Ltd, Renovo, Ltd, Signature
BioScience, Inc, Structural GenomiX, Inc, Transfusion
Technologies, Inc, Variagenics, Inc, Vasca, Inc
Canadian Medical Discoveries Fund
Address: About Us
Talbot Centre Canadian Medical Discoveries Fund Inc. (CMDF) and Candian
148 Fullarton Street, Suite 2006 Medical Discoveries Fund II Inc. (CMDF II) are labour-
London, ON N6A 5P3 sponsored investments funds (LSIFs) that focus exclusively on
CANADA the burgeoning health science sector.
The selection of early stage investments are influenced by the
Contact Info: following criteria:
T: (519) 858-1582
F: (519) 858-9121 The credibility of the principal investigators;
E: email@example.com the uniqueness of the discovery;
the protectability of the intellectual property under
Company Contacts: development; and
Dr. Calvin R. Stiller the commercial potential of the discovery.
Chairman & CEO
Michael Callaghan CMDF was established in 1994, and now has venture capital
Managing Director & Senior Vice investments in over 40 companies in the life sciences sector
President (mostly biotechnology, along with medical devices and health
services companies). The Fund has $311.6 million under
management as of September 30, 2002.
www.cmdf.com/ CMDF II is qualified for sale in Ontario and may be purchased
only by residents of Ontario. CMDF II was established on
August 31, 2002 with the amalgamation of two funds, CMDF
Venture Fund and CMDF Early Stage Fund, into one larger
fund, Canadian Medical Discoveries Fund II Inc.
CMDF typically provides equity financing in the range of
$250,000 to $5.0 million. No more than 10% of the capital
raised can be invested outside of Canada.
Aegera Therapeutics, AnorMED, Biomarin Pharmaceuticals,
Cellegy Pharmaceuticals, Centaur Pharmaceuticals, CryoCath
Technologies, Cubist Pharmaceuticals, Cytochroma, Ecopia
BioSciences, Excel-Tech Ltd., Gemin X Biotechnologies, GenSci
Regeneration Sciences, Genzyme Molecular Oncology,
GlycoDesign, Hemosol, MedInnova Partners, MedTech
Partners, MethylGene, Microbix Biosystems, Micrologix Biotech,
Networc Health, Neurocrine Biosciences, NeuroMed
Technologies, Neuroscience Development Partners, Nexia
Biotechnologies, NPS Pharmaceuticals, OptiMol, PhageTech,
Phytogen Life Sciences, Protiva Biotherapeutics, Star Biotech,
StressGen Biotechnologies, Systems Xcellence, T2C2, Tm
Bioscience, Twinstrand Therapeutics, UltraVision, University
Medical Discoveries, Variagenics, Veracel, WV CMDF Queen’s
Scientific Breakthrough Fund, Xillix Technologies
Cambridge Gateway Fund
Address: About Us
Richmond House The Cambridge Gateway Fund invests in emerging technology
16-20 Regent Street companies.
Cambridge, CB2 1DB
ENGLAND Preferred Stage
Map It Most investments are made in the early stages of a
company's existence. Will generally be the first or joint first
venture capital investor in a company.
T: +44 (0)1223 720 300 Geographic Focus
F: +44 (0)1223 720 330 A UK based company- have investments in Manchester and in
E: firstname.lastname@example.org Dunfermline, Scotland as well as in and around Cambridge.
While in general, prefers to be geographically close to
Company Contacts: portfolio.
Dr Catherine Beech
Founder and Director Capital
E: email@example.com Currently have £35.3 million at cost under management.
Cambridge Gateway Fund's investment in each company
Website URL: ranges from £1 to £3 million over the life of the investment.
www.cambridgegateway.com Will lead an investment or support a lead investor as part of a
Cambridge BioTechnology Limited, De Novo Pharmaceuticals
Limited, Intercytex Limited
Investor Cross Search
Click on the company name to see other investors in the
Cambridge BioTechnology, De Novo Pharmaceuticals,
BioMed Venture AG
Address: About Us
Breite Straße 6 - 8 Provides finance for promising, young life science companies
Hannover, D-30159 at every stage of their development, encouraging the planned
GERMANY growth of successful businesses.
Pre-seed / seed capital
Contact Info: Start-up financing
T: +49 (0) 511/35 39 65-0 Finance for business expansion
F: +49 (0) 511/35 39 65-44 Pre-IPO financing
E: firstname.lastname@example.org Bridge financing
Company Contacts: Investment Portfolio
Willi Weddrin MicroNet Medical Inc. , *Acri.Tec GmbH, AdnaGen AG,
CEO BioVisioN GmbH & Co. KG, Cranium Telemetrics, Intelligent
E: email@example.com Ion, Inc., Mesotec GmbH, St. Croix Medical, Excorp Medical
Uwe Hofmann Investor Cross Search
CEO Click on the company name to see other investors in the
E: firstname.lastname@example.org company.
Acri.Tec, AdnaGen, BioVisioN, Cranium Telemetrics, Excorp
Dr. Angelika Vlachou Medical, Intelligent Ion, Mesotec, MicroNet Medical, St. Croix
Investment Manager Medical
Dr. Kristina Felner